Drug reference
Abdominal infections | Acute gynaecological infections | Community-acquired pneumonia ▶BY INTRAVENOUS INFUSION ▶Adult: 1 g once daily Diabetic foot infections of the skin and soft-tissue ▶BY INTRAVENOUS INFUSION ▶Adult: 1 g once daily Surgical prophylaxis, colorectal surgery ▶BY INTRAVENOUS INFUSION ▶Adult: 1 g for 1 dose, dose to be completed within 1 hour before surgery
PDF page 570
CNS disorders—risk of seizures. elderly
PDF page 570
Avoid if history of immediate hypersensitivity reaction to beta-lactam antibacterials. Use with caution in patients with sensitivity to beta- lactam antibacterials.
PDF page 570
For choice of antibacterial therapy, see Antibacterials, use for prophylaxis p. 529, Diabetic foot infections, antibacterial therapy p. 533, Gastro-intestinal system infections, antibacterial therapy p. 535, Respiratory system infections, antibacterial therapy p. 538.
PDF page 570
→Appendix 1: carbapenems
PDF page 570
▶Common or very common Diarrhoea. headache. nausea. skin reactions. thrombophlebitis. vomiting ▶Uncommon Appetite decreased. arrhythmias. asthenia. confusion. constipation. dizziness. drowsiness. dry mouth. gastrointestinal discomfort. gastrointestinal disorders. hypotension. increased risk of infection. insomnia. oedema. pseudomembranous enterocolitis. seizure. swelling. taste altered. throat discomfort ▶Rare or very rare Anxiety. cholecystitis. depression. dysphagia. eye disorder. haemorrhage. hepatic disorders. hypersensitivity. hypoglycaemia. malaise. muscle cramps . nasal congestion. neutropenia. renal impairment. shoulder pain. syncope. thrombocytopenia. tremor ▶Frequency not known Aggression. delirium. drug reaction with eosinophilia and systemic symptoms (DRESS). gait abnormal. hallucination. level of consciousness decreased . movement disorders. muscle weakness. psychiatric disorder. tooth discolouration
PDF page 570
Manufacturer advises avoid unless potential benefit outweighs risk.
PDF page 570
Present in milk—manufacturer advises avoid.
PDF page 570
Dose adjustments Risk of seizures; max. 500 mg daily if eGFR less than 30 mL/minute/1.73 m2.
PDF page 570
For intravenous infusion (Invanz ®), give intermittently in Sodium chloride 0.9%. Reconstitute 1 g with 10 mL Water for injections or Sodium chloride 0.9%; dilute requisite dose in infusion fluid to a final concentration not exceeding 20 mg/mL; give over 30 minutes; incompatible with glucose solutions.
PDF page 570
There can be variation in the licensing of different medicines containing the same drug. Powder for solution for infusion ELECTROLYTES: May contain Sodium ▶Ertapenem (Non-proprietary) Ertapenem (as Ertapenem sodium) 1 gram Ertapenem 1g powder for concentrate for solution for infusion vials | 10 vial P s (Hospital only) ▶Invanz (Merck Sharp & Dohme Ltd) Ertapenem (as Ertapenem sodium) 1 gram Invanz 1g powder for solution for infusion vials | 1 vial P £31.65 DT = £31.65
PDF page 570
1 g once daily
First-line fragment. Read the complete Indications and Dose section above.
PDF page 570
1 g once daily
First-line fragment. Read the complete Indications and Dose section above.
PDF page 570
1 g for 1 dose, dose to be completed within
First-line fragment. Read the complete Indications and Dose section above.
PDF page 570
